References
- WallMEWaniMCCookCEPalmerKHMcphailATSimGAPlant Antitumor Agents. I. The Isolation and Structure of Camptothecin, a Novel Alkaloidal Leukemia and Tumor Inhibitor from Camptotheca acuminata1,2J Am Chem Soc1966881638883890
- KawatoYAonumaMHirotaYKugaHSatoKIntracellular roles of SN-38, a metabolite of the camptothecin derivative CPT-11, in the antitumor effect of CPT-11Cancer Res19915116418741911651156
- MonterrubioCPascual-PastoGCanoFSN-38-loaded nanofiber matrices for local control of pediatric solid tumors after subtotal resection surgeryBiomaterials201679697826695118
- LuJLiuCWangPThe self-assembling camptothecin-tocopherol prodrug: An effective approach for formulating camptothecinBiomaterials20156217618726057133
- BalaVRaoSBoydBJPrestidgeCAProdrug and nanomedicine approaches for the delivery of the camptothecin analogue SN38J Control Release20131721486123928356
- IyerRCroucherJLChornyMNanoparticle delivery of an SN38 conjugate is more effective than irinotecan in a mouse model of neuroblastomaCancer Lett2015360220521225684664
- SlatterJGSchaafLJSamsJPPharmacokinetics, metabolism, and excretion of irinotecan (CPT-11) following I.V. infusion of [(14)C] CPT-11 in cancer patientsDrug Metab Dispos200028442343310725311
- ZhaoHRubioBSapraPNovel prodrugs of SN38 using multiarm poly(ethylene glycol) linkersBioconjug Chem200819484985918370417
- ZhangHWangJMaoWNovel SN38 conjugate-forming nanoparticles as anticancer prodrug: in vitro and in vivo studiesJ Control Release2013166214715823266448
- SadekarSThiagarajanGBartlettKPoly(amido amine) dendrimers as absorption enhancers for oral delivery of camptothecinInt J Pharm2013456117518523933439
- OmarRBardoogoYLCorem-SalkmonEMizrahiBAmphiphilic star PEG-Camptothecin conjugates for intracellular targetingJ Control Release2017257768327677603
- XieJZhangXTengMSynthesis, characterization, and evaluation of mPEG-SN38 and mPEG-PLA-SN38 micelles for cancer therapyInt J Nanomedicine2016111677168627217746
- SepehriNRouhaniHTavassolianFSN38 polymeric nanoparticles: in vitro cytotoxicity and in vivo antitumor efficacy in xenograft balb/c model with breast cancer versus irinotecanInt J Pharm20144711–248549724879937
- PalakurthiSChallenges in SN38 drug delivery: current success and future directionsExpert Opin Drug Deliv201512121911192126206312
- BotellaPRivero-BucetaESafe approaches for camptothecin delivery: Structural analogues and nanomedicinesJ Control Release2017247285428027948
- OlusanyaTOBHaj AhmadRRIbegbuDMSmithJRElkordyAALiposomal Drug Delivery Systems and Anticancer DrugsMolecules2018234E90729662019
- AllenTMCullisPRLiposomal drug delivery systems: from concept to clinical applicationsAdv Drug Deliv Rev2013651364823036225
- SadzukaYTakabeHSonobeTLiposomalization of SN-38 as active metabolite of CPT-11J Control Release20051082–345345916182400
- CiTLiTChangGYuLDingJSimply mixing with poly(ethylene glycol) enhances the fraction of the active chemical form of antitumor drugs of camptothecin familyJ Control Release2013169332933523246468
- SafraTMuggiaFJeffersSPegylated liposomal doxorubicin (doxil): reduced clinical cardiotoxicity in patients reaching or exceeding cumulative doses of 500 mg/m2Ann Oncol20001181029103311038041
- FangTDongYZhangXXieKLinLWangHIntegrating a novel SN38 prodrug into the PEGylated liposomal system as a robust platform for efficient cancer therapy in solid tumorsInt J Pharm20165121394827544846
- ParkJWLiposome-based drug delivery in breast cancer treatmentBreast Cancer Res200243959912052251
- YangXZhaoXPhelpsMAA novel liposomal formulation of flavopiridolInt J Pharm20093651–217017418778761
- NiiTIshiiFEncapsulation efficiency of water-soluble and insoluble drugs in liposomes prepared by the microencapsulation vesicle methodInt J Pharm2005298119820515951143
- AlferievISIyerRCroucherJLNanoparticle-mediated delivery of a rapidly activatable prodrug of SN-38 for neuroblastoma therapyBiomaterials201551222925770994
- GoffLWBensonAB3rdLoRussoPMPhase I study of oral irinotecan as a single-agent and given sequentially with capecitabineInvest New Drugs201230129029820857171
- SchoemakerNEKuppensIEHuininkWWPhase I study of an oral formulation of irinotecan administered daily for 14 days every 3 weeks in patients with advanced solid tumoursCancer Chemother Pharmacol200555326327015592838
- SignorellRDLucianiPBrambillaDLerouxJCPharmacokinetics of lipid-drug conjugates loaded into liposomesEur J Pharm Biopharm201812818819929678733
- LeePCChiouYCWongJMPengCLShiehMJTargeting colorectal cancer cells with single-walled carbon nanotubes conjugated to anticancer agent SN-38 and EGFR antibodyBiomaterials201334348756876523937913